This ProZ/TV event is aimed at helping language professionals harness the power of AI tools to enhance your work and make informed business decisions for future success. In this event, we will delve into the world of AI-supported tools tailored specifically for language experts, providing practical insights and real-world examples.
Event access: this is a member-only event. If you are a ProZ.com paying member, register using the "Register for this event" button above and visit this page on the day and time of the event to attend (sessions will be broadcasted live). Not a member yet? Obtain unrestricted access to this event and to a full list of membership benefits by joining today. Check membership options »
Event recording: this event will be recorded and made available to ProZ.com Premium subscribers only (a few days after the event). If you are not a Premium subscriber, consider upgrading now. Check ProZ.com Premium » (Are you a paying member, but you couldn't attend the event because it is too early or too late in your time zone or due to special circumstances? Submit a support request »
00:45 Dec 26, 2023 |
English to Russian translations [PRO] Medical - Medical: Pharmaceuticals / investigator brochure | |||||||
---|---|---|---|---|---|---|---|
|
| ||||||
| Selected response from: Edgar Hermann Local time: 17:56 | ||||||
Grading comment
|
Summary of answers provided | ||||
---|---|---|---|---|
3 +1 | целевая доза, достигаемая пошаговым увеличением, 10 мг |
|
Summary of reference entries provided | |||
---|---|---|---|
|
Discussion entries: 2 | |
---|---|
целевая доза, достигаемая пошаговым увеличением, 10 мг Explanation: группы с пошаговым увеличением дозы до целевого значения 10 и 100 мг |
| |
Login to enter a peer comment (or grade) |
11 hrs |
Reference Reference information: https://rosoncoweb.ru/news/oncology/2023/12/06/ -------------------------------------------------- Note added at 11 hrs (2023-12-26 12:11:38 GMT) -------------------------------------------------- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980545/ Using the body’s immune system to recognize and kill cancer cells is an enticing prospect within oncology, showing great promise with several different therapeutic approaches. Among these are bispecific T-cell engagers (TCE), which can overcome some of the limitations of the body’s natural immune system by recruiting T cells to the tumor site and stimulating their activation and proliferation to help override the immune escape mechanisms developed by cancer cells. Emerging data from clinical trials of TCEs continue to provide insights on the efficacy and safety profiles of this class of therapy, and recent efforts have focused on optimizing clinical dose regimens to mitigate side effects related to overstimulation of the immune system, with particular emphasis on cytokine release syndrome (CRS) and neurotoxicity. For the currently approved TCEs, a key discovery was that by incrementally increasing the dose administered to a patient before reaching the target dose level, the body’s immune system could be primed in a more gradual manner, thereby modulating the balance between T cell activation and expansion, and cytokine-mediated efficacy and toxicity. This is known as step-up dosing, and various forms of this approach have been used to optimize TCE dose regimens to reduce the incidence or severity of CRS during clinical trials. |
| |
Login to enter a peer comment (or grade) |
Login or register (free and only takes a few minutes) to participate in this question.
You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.